BrainStorm Live Episode 2: Where Is The Biggest Initial Impact Of Amprion’s Technology?
Amprion’s CEO Dr. Russ Lebovitz discusses the early signs of Alzheimer’s, Parkinson’s and other neurodegenerative diseases. It’s frequently a notable decline of cognitive function with or without memory loss that is referred to as Minimal Cognitive Impairment or MCI. Approximately one-third (1/3) of patients with MCI may ultimately develop Alzheimer’s, but the other two-thirds (2/3) may either improve or may progress to other neurodegenerative diseases such as Parkinson’s.
Amprion’s groundbreaking Early Detection Testing℠ detects the Prions (aka misfolded proteins) that drive the progression of Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Our Prion Early Detection Science℠ also helps monitor the course of the disease on an on-going basis for each patient.
Early Signs of Alzheimer’s & Parkinson’s
And we think that it’s probably in the area for patients who suddenly present for the first time to their family members or their physician with confusion that it’s not clear whether it’s just the extreme aspects of normal aging or the earliest signs of Alzheimer’s, Parkinson’s or some sort of neurodegenerative disease. And that tends to fall into a class of diseases referred to as MCI, or Minimal Cognitive Impairment and over time, it’s known that minimal cognitive impairment, if you observe these patients, it’s a real mix of outcomes.
Approximately a third go on to dementia, most of which would be Alzheimer’s type dementia, and what we would expect to find in this group that go on to dementia, at the time they present with minimal cognitive impairment is high levels of misfolded protein, mainly Abeta and Tau. There’s a second group, another third, that just over at least the next three to five years, that normalize, they go back, they don’t get much worse and in many cases, go back to normal cognitive functioning.
So what we expect here is low levels of Abeta and Tau and if we can distinguish between these two, we can help at a very early time. If there are no misfolded proteins, we believe that there is no likelihood of a neurodegenerative progressive disease over the next five to ten years. There’s another third of patients that present with MCI that go on to other things. Some of them may stay the same. Others may develop motor so a certain number of Parkinson’s patients who go on to have mainly motor symptoms start off at the earliest time being a little confused and we think we can help there too.
There isn’t much known but we think this might be a group that has maybe more atypical patterns of misfolded proteins. Maybe a significant number of these have misfolded Synuclein and we’ll be able to predict outcomes for them as well.
Spread the Word. Join The Fight. #JTFBrainHealth